MX378995B - Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. - Google Patents

Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.

Info

Publication number
MX378995B
MX378995B MX2018008646A MX2018008646A MX378995B MX 378995 B MX378995 B MX 378995B MX 2018008646 A MX2018008646 A MX 2018008646A MX 2018008646 A MX2018008646 A MX 2018008646A MX 378995 B MX378995 B MX 378995B
Authority
MX
Mexico
Prior art keywords
diaza
spiro
carboxymethyl
oxo
amino
Prior art date
Application number
MX2018008646A
Other languages
English (en)
Other versions
MX2018008646A (es
Inventor
Achim Kless
Anita Wegert
Florian Jakob
Klaus Linz
Klaus Schiene
Paul Ratcliffe
René Michael Koenigs
Ruth Jostock
Sven Kühnert
Thomas Koch
Wolfgang Schröder
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2018008646A publication Critical patent/MX2018008646A/es
Publication of MX378995B publication Critical patent/MX378995B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano, su preparación y su uso en medicamentos, en particular en el tratamiento del dolor.
MX2018008646A 2016-01-13 2017-01-13 Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. MX378995B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16151014 2016-01-13
PCT/EP2017/025007 WO2017121649A1 (en) 2016-01-13 2017-01-13 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (2)

Publication Number Publication Date
MX2018008646A MX2018008646A (es) 2018-11-19
MX378995B true MX378995B (es) 2025-03-11

Family

ID=55129635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008646A MX378995B (es) 2016-01-13 2017-01-13 Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.

Country Status (28)

Country Link
US (7) US20170197971A1 (es)
EP (1) EP3402785B1 (es)
JP (1) JP6854823B2 (es)
KR (1) KR20180097733A (es)
CN (1) CN108779075B (es)
AR (1) AR107358A1 (es)
AU (1) AU2017206910B2 (es)
BR (1) BR112018014296B1 (es)
CA (1) CA3011180A1 (es)
CL (1) CL2018001910A1 (es)
CO (1) CO2018008449A2 (es)
CY (1) CY1122892T1 (es)
DK (1) DK3402785T3 (es)
EA (1) EA034904B1 (es)
EC (1) ECSP18060864A (es)
ES (1) ES2793384T3 (es)
HR (1) HRP20200809T1 (es)
HU (1) HUE049134T2 (es)
IL (1) IL260497B (es)
LT (1) LT3402785T (es)
MX (1) MX378995B (es)
PL (1) PL3402785T3 (es)
PT (1) PT3402785T (es)
RS (1) RS60224B1 (es)
SI (1) SI3402785T1 (es)
TW (1) TWI640514B (es)
WO (1) WO2017121649A1 (es)
ZA (1) ZA201805358B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX378995B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
FI3722284T3 (fi) 2016-01-13 2025-03-14 Gruenenthal Gmbh 3-((hetero-)aryyli)-8-amino-2-okso-1,3-diatsaspiro-[4.5]dekaanijohdannaisia
RS60223B1 (sr) 2016-01-13 2020-06-30 Gruenenthal Gmbh Derivati 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
PE20181375A1 (es) 2016-01-13 2018-08-28 Gruenenthal Chemie Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
HRP20201660T1 (hr) 2016-01-13 2021-03-05 Grünenthal GmbH Derivati 8-amino-2-okso-1,3-diazaspiro[4.5]dekana
WO2019039855A2 (ko) 2017-08-22 2019-02-28 주식회사 엘지화학 방열 소재의 혼합 방법
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
KR100855204B1 (ko) 2001-04-18 2008-09-01 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
IL165829A0 (en) 2002-07-05 2006-01-15 Targacept Inc N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2004241134A1 (en) 2003-05-23 2004-12-02 Zealand Pharma A/S Triaza-spiro compounds as nociceptin analogues and uses thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2007312391B2 (en) 2006-10-19 2012-06-21 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-HSD1 inhibitors for diabetes
EP2150552B1 (en) 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
JP5674635B2 (ja) * 2008-03-27 2015-02-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換された４−アミノシクロヘキサン誘導体
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
US8268853B2 (en) 2009-06-25 2012-09-18 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
JP2017521488A (ja) * 2014-06-13 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ 複素環式モルフィナン誘導体及びその使用
HRP20201660T1 (hr) 2016-01-13 2021-03-05 Grünenthal GmbH Derivati 8-amino-2-okso-1,3-diazaspiro[4.5]dekana
PE20181375A1 (es) 2016-01-13 2018-08-28 Gruenenthal Chemie Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
RS60223B1 (sr) 2016-01-13 2020-06-30 Gruenenthal Gmbh Derivati 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
EP3402811B1 (en) 2016-01-13 2022-03-30 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents
FI3722284T3 (fi) 2016-01-13 2025-03-14 Gruenenthal Gmbh 3-((hetero-)aryyli)-8-amino-2-okso-1,3-diatsaspiro-[4.5]dekaanijohdannaisia
AR107354A1 (es) 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
MX378995B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.

Also Published As

Publication number Publication date
TW201731823A (zh) 2017-09-16
BR112018014296B1 (pt) 2023-10-31
CY1122892T1 (el) 2021-10-29
US20200399280A1 (en) 2020-12-24
PT3402785T (pt) 2020-05-15
HUE049134T2 (hu) 2020-08-28
KR20180097733A (ko) 2018-08-31
PL3402785T3 (pl) 2020-07-27
IL260497B (en) 2020-08-31
CL2018001910A1 (es) 2018-10-19
US10807989B2 (en) 2020-10-20
CO2018008449A2 (es) 2018-09-10
SI3402785T1 (sl) 2020-07-31
AR107358A1 (es) 2018-04-25
US20230174540A1 (en) 2023-06-08
DK3402785T3 (da) 2020-04-20
US20180282341A1 (en) 2018-10-04
US20210179627A1 (en) 2021-06-17
JP2019501940A (ja) 2019-01-24
US20190382407A1 (en) 2019-12-19
ZA201805358B (en) 2024-03-27
EP3402785A1 (en) 2018-11-21
ECSP18060864A (es) 2018-08-31
US20170197971A1 (en) 2017-07-13
US20190106430A1 (en) 2019-04-11
EA201891612A1 (ru) 2019-01-31
WO2017121649A1 (en) 2017-07-20
EA034904B1 (ru) 2020-04-03
HRP20200809T1 (hr) 2020-08-07
MX2018008646A (es) 2018-11-19
TWI640514B (zh) 2018-11-11
BR112018014296A2 (pt) 2019-01-22
JP6854823B2 (ja) 2021-04-07
AU2017206910B2 (en) 2020-07-16
NZ745184A (en) 2024-03-22
LT3402785T (lt) 2020-04-10
CA3011180A1 (en) 2017-07-20
ES2793384T3 (es) 2020-11-13
AU2017206910A1 (en) 2018-08-30
CN108779075B (zh) 2022-01-11
RS60224B1 (sr) 2020-06-30
EP3402785B1 (en) 2020-02-26
CN108779075A (zh) 2018-11-09

Similar Documents

Publication Publication Date Title
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
MX378607B (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX379201B (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
NZ733174A (en) Quinazoline derivatives used to treat hiv
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MX2015010125A (es) Derivados de piridazinona-amidas.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
ZA201906153B (en) Pharmaceutical compositions for combination therapy
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders